Saturday 17 October 2026
Export MIRM’s income statement to Excel — free account
Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024. In the quarter to June 2026, revenue grew 37.9%, EPS fell 783.3%, free cash flow fell 681.5% and total debt rose 142.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
80.14
2.25
−2.73%
Follow MIRM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 6 | 6 |
+8 more TTM periods Free account |
| (702.97%) | (335.82%) | (8.65%) | (15.81%) | ||
| (97.15%) | (101.04%) | (3.09%) | (5.70%) | ||
ROIC |
(172.96%) | (298.98%) | (5.74%) | (11.56%) | |
Return on Tangible Assets |
(206.89%) | (267.15%) | (6.76%) | (11.15%) | |
Average Days of Receivables |
85.84 | 85.30 | 86.35 | 82.88 | |
Free Cash Flow per Share |
(4.32) | (3.44) | 1.09 | 0.88 | |
Free Cash Flow |
(273.74) | (202.55) | 54.87 | 44.32 | |
Capital Expenditures |
(46.47) | (31.58) | (0.95) | (0.37) | |
| Other line items | |||||
Cash ROIC |
(23.24%) | (21.57%) | 5.44% | 4.54% | |
Accounts Receivable Turnover |
4.90 | 4.98 | 5.17 | 5.37 | |
Accounts Payable Turnover |
5.50 | 2.99 | 8.27 | 8.73 | |
Inventory Turnover |
4.64 | 4.42 | 4.24 | 4.15 | |
Average Days of Payables |
75.70 | 204.48 | 35.01 | 46.87 | |
Days of Inventory on Hand |
83.27 | 87.85 | 90.62 | 92.53 | |
Tax Rate |
0.00 | 0.00 | 0.09 | 0.01 | |
Research and Development Expense of Revenue |
165.88% | 169.30% | 35.71% | 37.96% | |
Selling, General and Administrative Expense of Revenue |
50.78% | 51.90% | 49.30% | 50.81% | |
Share Based Compensation of Revenue |
16.82% | 16.12% | 13.70% | 13.91% | |
Interest Coverage |
(62.06) | (55.27) | (1.54) | (2.91) | |
Operating CF/Net income |
0.26 | 0.21 | (2.39) | (1.08) | |
Depreciation/Fixed assets |
12.41 | 11.12 | 13.95 | 20.32 | |
Capex/Depreciation |
(1.66) | (1.18) | (0.04) | (0.01) | |
Revenue per Share |
9.75 | 9.68 | 10.39 | 9.32 | |
Operating CF per Share |
(3.59) | (2.91) | 1.11 | 0.88 | |
Capex per Share |
(0.73) | (0.54) | (0.02) | (0.01) | |
Capex to Sales |
0.08 | 0.06 | 0.00 | 0.00 |
Columns are period end dates